GE HealthCare and Mayo Clinic announced the MI-BET research collaboration, a novel theranostics study designed to explore a more personalized approach to radioligand therapy (RLT) for patients with advanced prostate cancer. The collaboration aims to evaluate whether imaging- and biomarker-informed insights can support individualized treatment decisions, potentially expanding access to theranostics. This initiative is a direct result of the 2023 Strategic Radiology Research Alliance between Mayo Clinic and GE HealthCare, which focuses on transforming the experience of patients and clinicians in radiology and the delivery of novel therapies.

Radioligand therapy is an emerging treatment approach within theranostics that combines targeted radiopharmaceutical diagnostics and therapies, allowing clinicians to identify and treat cancer with greater precision. Currently, many patients receiving RLT follow a standardized preset number of treatment cycles. The MI-BET study is designed to assess if treatment can be adapted based on an individual patient's disease response over time, including the possibility of pausing RLT treatment.

Key Objectives of MI-BET

The study focuses on leveraging imaging and data to inform treatment decisions. The primary goals include:

• Exploring a personalized approach to radioligand therapy.
• Evaluating the efficacy of imaging- and biomarker-informed insights.
• Supporting individualized care plans for advanced prostate cancer patients.

Background of the Collaboration

The partnership builds on the 2023 Strategic Radiology Research Alliance. This alliance was established to enhance patient and clinician experiences in radiology and facilitate the delivery of novel therapies. The MI-BET study represents a significant step in this ongoing collaboration, aiming to refine treatment protocols in theranostics.

The Law Offices of Frank R. Cruz continues its investigation of GE HealthCare Technologies Inc. on behalf of investors concerning possible violations of federal securities laws. The investigation focuses on the company's financial disclosures and subsequent market impact following its first-quarter 2026 earnings report.

On April 29, 2026, GE HealthCare reported its financial results for the first quarter of 2026. The company reported adjusted earnings per share of $0.99 and cut its full-year 2026 adjusted EPS guidance to a range of $4.80 to $5.00, down from prior guidance of $4.95 to $5.15.

During the earnings call, management disclosed that profit performance in the first quarter was impacted by a recall associated with a PDx supplier. Additionally, the company stated that year-over-year margin performance was affected by declines in PCS and the PDx supplier issue.

Following this news, the price of GE HealthCare shares declined by $9.01 per share, or 13.2%, to close at $59.49 per share on April 29, 2026.

Key Financial Details

Investors who purchased GE HealthCare securities and have information or questions regarding the investigation are encouraged to contact The Law Offices of Frank R. Cruz. The firm is located at 2121 Avenue of the Stars, Suite 800, Century City, California 90067, and can be reached at 310-914-5007 or via email at info@frankcruzlaw.com .